– UK, London – Graft Polymer (UK) PLC (LON: GPL), an innovative biotechnology company focused on co-developing therapeutics for mental health disorders, announced the appointment of Dennis Purcell to its Board of Directors as Chairman, replacing Nicholas Nelson who remains on the Board as a Non-Executive Director.
About Dennis Purcell
A pioneer in the biotechnology industry, Dennis Purcell is the Founder and former Senior Managing Partner of Aisling Capital LLC, a leading U.S. healthcare investment firm which has raised $1.8 billion since its inception. Prior to founding Aisling Capital, he served as Managing Director of the Healthcare Investment Banking Group at Hambrecht & Quist, where he led over $20 billion in financing for the pharmaceutical, biotechnology and medical device sectors of the healthcare industry.
Dennis Purcell has extensive experience in helping biotechnology companies access the capital markets, along with deep involvement in mergers, acquisitions, and strategic partnerships. His leadership has been instrumental in the success of numerous early-stage companies. As Graft Polymer continues to advance its co-development of therapeutics for mental health disorders, his knowledge and global network will be invaluable in expanding the Company’s presence in both U.S. and European markets.
As Chairman, Dennis Purcell will guide the Company’s collaborations, the first of which is with Awakn Life Sciences Corp., a biotechnology company focused on addiction and mental health. This partnership aims to co-develop a new class of medicines for the treatment of trauma-related mental health disorders, including Post-Traumatic Stress Disorder. Mr Purcell was a Special Adviser to the CEO for Awakn for a short period during 2022.
Dennis Purcell said: “I am thrilled to join Graft Polymer’s Board at such an exciting juncture. The Company’s collaboration model, starting with Awakn, is poised to make a significant impact in the biopharmaceutical sector – specifically in the area of treating addiction and mental health issues, where there is an enormous opportunity. I look forward to working closely with my fellow Board members and the management team to drive growth, enhance shareholder value, and bring transformational solutions to patients in need.”
About Graft Polymer (UK) Plc
Graft Polymer (UK) Plc is an innovative biotechnology company focused on developing intellectual property relating to the treatment of mental health and substance use disorders, and the co-development of therapeutics for mental health disorders. Our mission is to improve outcomes for individuals suffering from these conditions, with an initial focus on trauma-related mental health disorders, such as PTSD, which affects approximately 13 million adults in the U.S. and 20 million in US, UK, and key EU markets.
For more information : https://graftpolymer.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.